SARRC’s Research Department is committed to identifying best practices for autism spectrum disorder (ASD) screening, diagnosis, and intervention, but we cannot do it alone. We look to individuals impacted by autism and their families to participate in our current research projects. Our research program utilizes rigorous research methods and is informed by the needs, preferences, and values of the community that we serve. Note: A stipend may be provided to cover the cost of time and travel.
The Acadia Study is a 14-week study to learn about irritability associated with autism spectrum disorder (ASD). We are enrolling children and adolescents with ASD ages 5-17 for a clinical study involving an investigational medication. The purpose of this study is to evaluate the effectiveness and safety of the study medication for the treatment of irritability associated with ASD, as well as the efficacy in the treatment of other symptoms associated with ASD, such as social and communication benefits and repetitive behaviors.
This study will examine if a new investigational medical device called the EarliPoint™ Evaluation for Autism Spectrum Disorder (ASD), can be used to diagnose autism in children ages 31-84 months. The device detects the presence and severity of ASD and related developmental delays.
The EarliPoint™ Evaluation for ASD (the device) tracks where children are looking as they watch videos on a screen, which shows us how typically developing children and children with autism visually explore the world differently. This study is looking at whether the device can give comparable results to current diagnostic tests performed by clinicians.
SARRC is currently enrolling adults with autism ages 18 and older to participate in a study that aims to compare the outcomes of 100 autistic adults who are currently enrolled or who are graduates of the First Place Transition Academy in Phoenix. Participants will help our team improve programs, services and interventions for teens and adults with autism.
In the IRIS research study, we are looking to find out whether an investigational drug might improve the symptoms of ASD that often make social interaction challenging. To qualify, participants must be 18 to 45 years of age; have a diagnosis of autism spectrum disorder (ASD) have a relative, housemate, friend, or another study partner to assist during the study, and attend clinic visits.
SARRC is currently enrolling individuals between the ages of 2.5-5 years with ASD in the Leucovorin Study to assess the efficacy of an investigational natural treatment known as Levoleucovorin in enhancing language and social communication skills in children diagnosed with ASD. The 16-week clinical trial will help our team learn more about language and social communication in children with autism.
The MEASURE Study is a clinical study examining a new investigational medical device, the EarliPoint™ Assessment for autism spectrum disorder in children ages 15-78 months. SARRC is currently enrolling toddlers with and without an autism diagnosis to assess the device’s effectiveness in monitoring a child’s treatment progress.
The Simons Foundation Autism Research Initiative is offering SPARK—an online, long-term study of genetics and autism. SPARK will collect and analyze genetic samples (saliva) from all participants to help autism researchers learn about genetic and non-genetic causes of autism. SPARK is open to all individuals with a professional diagnosis of autism, as well as their parents. Participation can take place either in your home via a mail-in kit or at SARRC.